首页> 外国专利> METHODS OF TREATING, REDUCING THE INCIDENCE OF, AND/OR PREVENTING ISCHEMIC EVENTS

METHODS OF TREATING, REDUCING THE INCIDENCE OF, AND/OR PREVENTING ISCHEMIC EVENTS

机译:治疗,减少缺血性事件和/或预防缺血性事件的方法

摘要

The present invention relates to methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising (1) administering intravenously a 30 μg/kg bolus of cangrelor/kg before the start of PCI; (2) administering intravenously a 4 μg/kg/min continuous infusion of cangrelor after administration of the bolus; wherein the administration of the continuous infusion of cangrelor continues for the longer of (a) at least 2 h, or (b) the duration of PCI; and (3) administering a loading oral dose of ticagrelor in an amount of 180 mg (a) during administration of the continuous infusion of cangrelor, or (b) after discontinuation of the administration of the continuous infusion. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization and mortality.
机译:本发明涉及在经历经皮冠状动脉介入治疗(PCI)的患者中治疗,降低其发生率和/或预防其缺血事件的方法,其包括(1)在静脉内给予坎格雷洛尔/ kg静脉推注30μg/ kg坎格雷洛尔/ kg。开始PCI; (2)在推注后静脉内以4μg/ kg / min连续输注坎格雷洛。其中连续输注坎格雷洛的给药持续(a)至少2小时或(b)PCI持续时间中的较长时间; (3)在180mg坎格雷洛尔的连续输注过程中,或(b)在中断连续输注后,给予替卡格雷的负荷口服剂量为180mg。该方法可以进一步包括向患者施用另外的治疗剂,该另外的治疗剂包含P2Y 12 抑制剂。缺血事件可能包括支架血栓形成,心肌梗塞,缺血驱动的血运重建和死亡率。

著录项

  • 公开/公告号EA034550B1

    专利类型

  • 公开/公告日2020-02-19

    原文格式PDF

  • 申请/专利权人 CHIESI FARMACEUTICI S.P.A.;

    申请/专利号EA20150091683

  • 发明设计人 CLIVE ARTHUR;SIMONA;JAYNE;DAVID J.;

    申请日2013-05-29

  • 分类号A61K31/7064;

  • 国家 EA

  • 入库时间 2022-08-21 11:17:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号